{"id":"dornase-alfa-pulmozyme","safety":{"commonSideEffects":[{"rate":"12-13%","effect":"Voice hoarseness"},{"rate":"8-10%","effect":"Pharyngitis"},{"rate":"5-7%","effect":"Laryngitis"},{"rate":"4-5%","effect":"Rash"},{"rate":"3-4%","effect":"Chest pain"},{"rate":"2-3%","effect":"Dyspnea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"In cystic fibrosis patients, neutrophil-derived DNA accumulates in thick airway secretions, contributing to airway obstruction and chronic infection. Dornase alfa enzymatically degrades this extracellular DNA, reducing sputum viscosity and improving mucociliary clearance. This allows better airflow and reduces bacterial colonization and inflammation in the lungs.","oneSentence":"Dornase alfa is a recombinant human deoxyribonuclease that cleaves extracellular DNA in airway secretions, reducing mucus viscosity and improving clearance in cystic fibrosis lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:29.951Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis with FEV1 ≥40% predicted"},{"name":"Improvement of pulmonary function in cystic fibrosis patients"}]},"trialDetails":[{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT07432373","phase":"","title":"Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection","status":"NOT_YET_RECRUITING","sponsor":"National University of Malaysia","startDate":"2026-04-01","conditions":"Pleural Infection","enrollment":80},{"nctId":"NCT05903417","phase":"NA","title":"Pleural Irrigation With Normal Saline Versus Intrapleural Fibrinolytic","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2023-07-10","conditions":"Pleural Infection","enrollment":40},{"nctId":"NCT04785066","phase":"PHASE2","title":"Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target)","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2022-08-19","conditions":"Ischemic Stroke","enrollment":39},{"nctId":"NCT07361224","phase":"PHASE1","title":"Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.","status":"NOT_YET_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2026-02","conditions":"Large B-Cell Lymphoma (LBCL)","enrollment":12},{"nctId":"NCT04095676","phase":"NA","title":"VATS Surgery Compared to Drainage in the Treatment of Pleural Empyema","status":"RECRUITING","sponsor":"Thomas Decker Christensen","startDate":"2022-10-30","conditions":"Pleural Empyema","enrollment":184},{"nctId":"NCT07121322","phase":"PHASE2","title":"Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.","status":"RECRUITING","sponsor":"National Cancer Institute, Slovakia","startDate":"2025-07-30","conditions":"Refractory Germ Cell Tumors, Dornase Alfa","enrollment":33},{"nctId":"NCT03368092","phase":"PHASE3","title":"Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2019-03-04","conditions":"Multiple Trauma, Respiratory Distress Syndrome, Adult","enrollment":500},{"nctId":"NCT06723717","phase":"PHASE2","title":"Efficacy of Daily IV Administration of Dornase Alfa Up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence At 6 Months","status":"NOT_YET_RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2025-04","conditions":"Ruptured Aneurysm of Intracranial Artery, SAH (Subarachnoid Hemorrhage), Delayed Cerebral Ischemia","enrollment":304},{"nctId":"NCT04359654","phase":"PHASE2","title":"Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-06-16","conditions":"COVID-19 (Coronavirus Disease 2019), Hypoxia","enrollment":41},{"nctId":"NCT04378153","phase":"","title":"Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy","status":"COMPLETED","sponsor":"Nicole Hamblett","startDate":"2020-08-25","conditions":"Cystic Fibrosis","enrollment":987},{"nctId":"NCT06350474","phase":"NA","title":"Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study","status":"COMPLETED","sponsor":"Nicole Hamblett","startDate":"2020-08-25","conditions":"Cystic Fibrosis","enrollment":477},{"nctId":"NCT05392855","phase":"NA","title":"Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)","status":"TERMINATED","sponsor":"University of Missouri-Columbia","startDate":"2023-09-05","conditions":"Cystic Fibrosis, Mucociliary Clearance Defect","enrollment":6},{"nctId":"NCT05203224","phase":"PHASE2","title":"Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2022-02-18","conditions":"Ischemic Stroke","enrollment":300},{"nctId":"NCT05880524","phase":"PHASE2","title":"Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)","status":"NOT_YET_RECRUITING","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2024-12","conditions":"Ischemic Stroke, Inflammatory Response","enrollment":36},{"nctId":"NCT03213834","phase":"PHASE4","title":"Fibrinolytic Therapy Versus Medical Thoracoscopy","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-09-14","conditions":"Pleural Diseases","enrollment":5},{"nctId":"NCT04320381","phase":"","title":"Qualitative Understanding of Experiences With the SIMPLIFY Trial","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2020-12-23","conditions":"Cystic Fibrosis, Drug Withdrawal","enrollment":115},{"nctId":"NCT04409925","phase":"PHASE1","title":"DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2020-12-25","conditions":"COVID-19 Infection","enrollment":15},{"nctId":"NCT05139901","phase":"PHASE4","title":"Usefulness of DORNASE in COVID-19 on HFNO","status":"TERMINATED","sponsor":"University Medical Centre Ljubljana","startDate":"2021-12-01","conditions":"COVID-19 Pneumonia","enrollment":10},{"nctId":"NCT05663255","phase":"","title":"Effectiveness of CFTR Modulators According to Co-therapy","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2023-03-01","conditions":"Cystic Fibrosis","enrollment":1990},{"nctId":"NCT01478698","phase":"PHASE1","title":"The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients","status":"TERMINATED","sponsor":"Sir Charles Gairdner Hospital","startDate":"2016-01-01","conditions":"Peritoneal Dialysis, Peritoneal Dialysis, Continuous Ambulatory","enrollment":5},{"nctId":"NCT00843817","phase":"PHASE4","title":"RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2009-04","conditions":"Cystic Fibrosis","enrollment":15},{"nctId":"NCT05279391","phase":"NA","title":"Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19","status":"UNKNOWN","sponsor":"Democritus University of Thrace","startDate":"2020-10-25","conditions":"COVID-19 Severe Respiratory Failure","enrollment":150},{"nctId":"NCT04355364","phase":"PHASE3","title":"Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2020-04-21","conditions":"COVID-19, Acute Respiratory Distress Syndrome","enrollment":77},{"nctId":"NCT04402944","phase":"PHASE2","title":"Pulmozyme to Improve COVID-19 ARDS Outcomes","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2020-07-05","conditions":"COVID","enrollment":60},{"nctId":"NCT02702518","phase":"PHASE1, PHASE2","title":"rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2016-04","conditions":"Ocular Graft vs Host Disease, Dry Eye","enrollment":58},{"nctId":"NCT04915586","phase":"NA","title":"Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2019-12-30","conditions":"Loculated Empyema","enrollment":30},{"nctId":"NCT04445285","phase":"PHASE2","title":"Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure","status":"RECRUITING","sponsor":"Jon Simmons","startDate":"2020-04-28","conditions":"Covid19","enrollment":44},{"nctId":"NCT04402970","phase":"PHASE3","title":"Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2020-06-19","conditions":"SARS-CoV 2, ARDS","enrollment":30},{"nctId":"NCT02135588","phase":"PHASE1","title":"Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions","status":"UNKNOWN","sponsor":"Eastern Regional Medical Center","startDate":"2013-10","conditions":"Loculated or Non-draining Malignant Pleural Effusions","enrollment":10},{"nctId":"NCT04387786","phase":"","title":"Dornase Alfa Administered to Patients With COVID-19 (DACOVID)","status":"COMPLETED","sponsor":"Feinstein Institute for Medical Research","startDate":"2020-03-31","conditions":"COVID-19, Mechanical Ventilation","enrollment":5},{"nctId":"NCT04459325","phase":"PHASE3","title":"Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2020-06-01","conditions":"COVID-19, Coronavirus Disease 2019","enrollment":100},{"nctId":"NCT04468100","phase":"PHASE3","title":"Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2017-08-30","conditions":"Cystic Fibrosis, Fibrosis","enrollment":100},{"nctId":"NCT04432987","phase":"PHASE2","title":"Dornase Alpha for the Treatment of COVID-19","status":"UNKNOWN","sponsor":"Acibadem University","startDate":"2020-05-25","conditions":"COVID-19","enrollment":60},{"nctId":"NCT01717742","phase":"PHASE3","title":"Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2012-12","conditions":"Pleural Empyema","enrollment":97},{"nctId":"NCT03994380","phase":"PHASE1, PHASE2","title":"Use of DNAse in Neutrophilic Asthma","status":"UNKNOWN","sponsor":"National Jewish Health","startDate":"2020-02-12","conditions":"Neutrophilic Asthma","enrollment":10},{"nctId":"NCT01357447","phase":"PHASE1","title":"Pulmozyme for Sjogren's Associated Cough","status":"WITHDRAWN","sponsor":"UConn Health","startDate":"2011-05","conditions":"Sjogren's Syndrome, Cough","enrollment":""},{"nctId":"NCT02193490","phase":"PHASE1, PHASE2","title":"DNase Treatment for Dry Eyes","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2014-07","conditions":"Dry Eye","enrollment":47},{"nctId":"NCT03586076","phase":"PHASE1","title":"A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects","status":"COMPLETED","sponsor":"JHL Biotech, Inc.","startDate":"2018-01-26","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT01952470","phase":"PHASE2","title":"Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.","status":"COMPLETED","sponsor":"The Alfred","startDate":"2013-10-31","conditions":"Lung Transplant Infection, Lower Respiratory Tract Infection","enrollment":32},{"nctId":"NCT00179998","phase":"PHASE2","title":"Effectiveness of Pulmozyme in Infants With Cystic Fibrosis","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2005-01","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT01356147","phase":"PHASE4","title":"Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2011-05","conditions":"Pulmonary Infections","enrollment":11},{"nctId":"NCT01155752","phase":"PHASE3","title":"Pulmozyme in Cystic Fibrosis With Sinusitis","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-07","conditions":"Sinusitis, Cystic Fibrosis","enrollment":""},{"nctId":"NCT00671723","phase":"NA","title":"Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2006-10","conditions":"Atelectasis","enrollment":33},{"nctId":"NCT00311506","phase":"","title":"A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"1999-10","conditions":"Cystic Fibrosis","enrollment":25},{"nctId":"NCT00434278","phase":"PHASE4","title":"A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-03","conditions":"Cystic Fibrosis","enrollment":27},{"nctId":"NCT00680316","phase":"PHASE4","title":"A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-06","conditions":"Cystic Fibrosis","enrollment":3},{"nctId":"NCT02722122","phase":"PHASE2","title":"Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®","status":"UNKNOWN","sponsor":"Protalix","startDate":"2016-05","conditions":"Cystic Fibrosis","enrollment":15},{"nctId":"NCT00169962","phase":"PHASE2","title":"Study of Pulmozyme to Treat Severe Asthma Episodes","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2004-01","conditions":"Asthma","enrollment":51},{"nctId":"NCT00419380","phase":"PHASE4","title":"Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-01","conditions":"Otitis Media","enrollment":40},{"nctId":"NCT02168387","phase":"PHASE4","title":"Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient","status":"COMPLETED","sponsor":"Duke University","startDate":"2010-12","conditions":"Atelectasis","enrollment":39},{"nctId":"NCT00534079","phase":"PHASE3","title":"Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"University of Jena","startDate":"2007-09","conditions":"Cystic Fibrosis, Rhinosinusitis","enrollment":23},{"nctId":"NCT00265434","phase":"PHASE3","title":"Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"University of Jena","startDate":"2005-12","conditions":"Cystic Fibrosis, Chronic Rhinosinusitis","enrollment":5},{"nctId":"NCT00416182","phase":"PHASE2","title":"Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2006-12","conditions":"Sinusitis, Cystic Fibrosis","enrollment":16},{"nctId":"NCT01712334","phase":"PHASE4","title":"A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-12","conditions":"Cystic Fibrosis","enrollment":99},{"nctId":"NCT00557089","phase":"PHASE4","title":"The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2008-01","conditions":"Cystic Fibrosis","enrollment":17},{"nctId":"NCT00536952","phase":"EARLY_PHASE1","title":"Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2008-02","conditions":"Head and Neck Cancer","enrollment":36},{"nctId":"NCT01095276","phase":"NA","title":"Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-11","conditions":"Atelectasis, Ventilation, Mechanical","enrollment":30},{"nctId":"NCT00117208","phase":"PHASE2","title":"Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis","status":"COMPLETED","sponsor":"Syntara","startDate":"2005-11","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT00502632","phase":"PHASE2, PHASE3","title":"Dornase Alfa and Urokinase for Kids With Pleural Empyema","status":"UNKNOWN","sponsor":"Azienda Ospedaliera di Padova","startDate":"2007-10","conditions":"Pleural Empyema","enrollment":94},{"nctId":"NCT00204685","phase":"PHASE2, PHASE3","title":"Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2003-08","conditions":"Long Term Ventilation","enrollment":540}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dornase alfa (Pulmozyme)","genericName":"Dornase alfa (Pulmozyme)","companyName":"University of Jena","companyId":"university-of-jena","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dornase alfa is a recombinant human deoxyribonuclease that cleaves extracellular DNA in airway secretions, reducing mucus viscosity and improving clearance in cystic fibrosis lungs. Used for Cystic fibrosis with FEV1 ≥40% predicted, Improvement of pulmonary function in cystic fibrosis patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}